Below you find a list of the most recent publications from the Moriggl lab (2018-2020). For a complete list of publications please follow this link.

2020

Cancers special issue “Targeting STAT3 and STAT5 in Cancers” edited by Prof. Dr. Richard Moriggl, Prof. Dr. Patrick Gunning and Prof. Dr. György Miklós Keserü.
Targeting STAT3 and STAT5 in Cancers

STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue.
Kaltenecker D, Spirk K, Ruge F, Grebien F, Herling M, Rupprecht A, Kenner L, Pohl EE, Mueller KM, Moriggl R. Mol Metab. 2020 May 27:101026. doi: 10.1016/j.molmet.2020.101026. Online ahead of print. PMID: 32473405

CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia.
Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson RA, Moriggl RH, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F. Blood. 2020 Apr 28:blood.2019003267. doi: 10.1182/blood.2019003267. Online ahead of print. PMID: 32344427

STAT5 is Expressed in CD34+/CD38 Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms.
Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl R, Valent P.
Cancers (Basel). 2020 Apr 21;12(4). pii: E1021. doi: 10.3390/cancers12041021.

The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5.
Kadekar D, Agerholm R, Rizk J, Neubauer HA, Suske T, Maurer B, Viñals MT, Comelli EM, Taibi A, Moriggl R, Bekiaris V.
J Clin Invest. 2020 Apr 13. pii: 131241. doi: 10.1172/JCI131241.

Advances in covalent kinase inhibitors.
Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT.
Chem Soc Rev. 2020 Mar 30. doi: 10.1039/c9cs00720b. Review.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.
Haematologica. 2020 Jan 31;105(2):435-447. doi: 10.3324/haematol.2019.216986.

AMPK leads to phosphorylation of the transcription factor Nrf2, tuning transactivation of selected target genes.
Matzinger M, Fischhuber K, Pölöske D, Mechtler K, Heiss EH.
Redox Biol. 2020 Jan; 29:101393. doi: 10.1016/j.redox.2019.101393

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.
Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F.
Cancers (Basel). 2020 Jan 18;12(1). pii: E240. doi: 10.3390/cancers12010240. Review.

2019

Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function.
Lercher A, Bhattacharya A, Popa AM, Caldera M, Schlapansky MF, Baazim H, Agerer B, Gürtl B, Kosack L, Májek P, Brunner JS, Vitko D, Pinter T, Genger JW, Orlova A, Pikor N, Reil D, Ozsvár-Kozma M, Kalinke U, Ludewig B, Moriggl R, Bennett KL, Menche J, Cheng PN, Schabbauer G, Trauner M, Klavins K, Bergthaler A.
Immunity. 2019 Dec 17;51(6):1074-1087.e9. doi: 10.1016/j.immuni.2019.10.014. Epub 2019 Nov 26.

JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Mohrherr J, Haber M, Breitenecker K, Aigner P, Moritsch S, Voronin V, Eferl R, Moriggl R, Stoiber D, Győrffy B, Brcic L, László V, Döme B, Moldvay J, Dezső K, Bilban M, Popper H, Moll HP, Casanova E.
Int J Cancer. 2019 Dec 15;145(12):3376-3388. doi: 10.1002/ijc.32624.

Direct Targeting Options for STAT3 and STAT5 in Cancer.
Orlova A, Wagner C, de Araujo ED, Bajusz D, Neubauer HA, Herling M, Gunning PT, Keserű GM, Moriggl R.
Cancers (Basel). 2019 Dec 3;11(12). pii: E1930. doi: 10.3390/cancers11121930. Review.

Editorial: Cytokines in liver diseases.
langumaran S, Moriggl R, Kalvakolanu DV.
Cytokine. 2019 Dec;124:154608. doi: 10.1016/j.cyto.2018.12.001. Epub 2018 Dec 16.

Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases.
Duvigneau JC, Luís A, Gorman AM, Samali A, Kaltenecker D, Moriggl R, Kozlov AV.
Cytokine. 2019 Dec;124:154577. doi: 10.1016/j.cyto.2018.10.018. Epub 2018 Nov 14.

Hepatic growth hormone – JAK2 – STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.
Kaltenecker D, Themanns M, Mueller KM, Spirk K, Suske T, Merkel O, Kenner L, Luís A, Kozlov A, Haybaeck J, Müller M, Han X, Moriggl R.
Cytokine. 2019 Dec;124:154569. doi: 10.1016/j.cyto.2018.10.010. Epub 2018 Oct 30.

STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice.
Kaltenecker D, Themanns M, Mueller KM, Spirk K, Golob-Schwarzl N, Friedbichler K, Kenner L, Haybaeck J, Moriggl R.
Cytokine. 2019 Dec;124:154573. doi: 10.1016/j.cyto.2018.10.014. Epub 2018 Oct 28.

Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.
Powell JA, Pitman MR, Zebol JR, Moretti PAB, Neubauer HA, Davies LT, Lewis AC, Dagley LF, Webb AI, Costabile M, Pitson SM.
Biochem J. 2019 Nov 15;476(21):3211-3226. doi: 10.1042/BCJ20190245.

Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.
de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT.
Cancers (Basel). 2019 Nov 8;11(11). pii: E1757. doi: 10.3390/cancers11111757. Review.

Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer.
Unterleuthner D, Neuhold P, Schwarz K, Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C, Hengstschläger M, Eferl R, Moriggl R, Sommergruber W, Gerner C, Dolznig H.
Angiogenesis. 2019 Oct 30. doi: 10.1007/s10456-019-09688-8.

The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.
Orlova A, Neubauer HAMoriggl R.
Haematologica. 2019 Oct;104(10):1907-1909. doi: 10.3324/haematol.2019.225862. 

STAT3 and STAT5 Activation in Solid Cancers.
Igelmann S, Neubauer HA, Ferbeyre G.
Cancers (Basel). 2019 Sep 25;11(10). pii: E1428. doi: 10.3390/cancers11101428. Review.

STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia.
Klein K, Witalisz-Siepracka A, Maurer B, Prinz D, Heller G, Leidenfrost N, Prchal-Murphy M, Suske T, Moriggl R, Sexl V.
Leukemia. 2019 Sep;33(9):2336-2340. doi: 10.1038/s41375-019-0471-3. Epub 2019 Apr 9.

STAT3β is a tumor suppressor in acute myeloid leukemia.
Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, Just V, Moll HP, Yeroslaviz A, Fischer MJM, Kenner L, Győrffy B, Sill H, Grebien F, Moriggl R, Casanova E, Stoiber D.
Blood Adv. 2019 Jul 9;3(13):1989-2002. doi: 10.1182/bloodadvances.2018026385.

STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice.
Boutillon F, Pigat N, Sala LS, Reyes-Gomez E, Moriggl R, Guidotti JE, Goffin V.
Cancers (Basel). 2019 Jul 2;11(7). pii: E929. doi: 10.3390/cancers11070929.

Structural and functional consequences of the STAT5BN642H driver mutation.
de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, Rülicke T, Dong A, Ravichandran M, Brown PJ, Audette GF, Rauscher S, Dhe-Paganon S, Moriggl R, Gunning PT.
Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7.

Parathyroid hormone induces a browning program in human white adipocytes.
Hedesan OC, Fenzl A, Digruber A, Spirk K, Baumgartner-Parzer S, Bilban M, Kenner L, Vierhapper M, Elbe-Bürger A, Kiefer FW.
Int J Obes (Lond). 2019 Jun;43(6):1319-1324. doi: 10.1038/s41366-018-0266-z. Epub 2018 Dec 5.

Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells. Muller A, Gasch J, Albring KF, Aberger F, Nivarthi H, Khemeri M, Moriggl R, Friedrich KH. Neoplasma. 2019 May 23;66(3):357-366. doi: 10.4149/neo_2018_180731N560. Epub 2018 Dec 12.

Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis.
Liu R, Moriggl R, Zhang D, Li H, Karns R, Ruan HB, Niu H, Mayhew C, Watson C, Bangar H, Cha SW, Haslam D, Zhang T, Gilbert S, Li N, Helmrath M, Wells J, Denson L, Han X.
Life Sci Alliance. 2019 Apr 4;2(2). pii: e201900296. doi: 10.26508/lsa.201900296. Print 2019 Apr.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.
Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21

Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival.
Rauth M, Freund P, Orlova A, Grünert S, Tasic N, Han X, Ruan HB, Neubauer HA, Moriggl R.
Int J Mol Sci. 2019 Feb 27;20(5). pii: E1028. doi: 10.3390/ijms20051028. Review.

Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma.
Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM.
Oncogene. 2019 Feb;38(8):1151-1165. doi: 10.1038/s41388-018-0504-9. Epub 2018 Sep 24.

Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J.
Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9.

High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12
Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J.
Transl Oncol. 2019 Feb;12(2):256-268. doi: 10.1016/j.tranon.2018.10.010. Epub 2018 Nov 12.

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease.
Kosack L, Wingelhofer B, Popa A, Orlova A, Agerer B, Vilagos B, Majek P, Parapatics K, Lercher A, Ringler A, Klughammer J, Smyth M, Khamina K, Baazim H, de Araujo ED, Rosa DA, Park J, Tin G, Ahmar S, Gunning PT, Bock C, Siddle HV, Woods GM, Kubicek S, Murchison EP, Bennett KL, Moriggl R, Bergthaler A.
Cancer Cell. 2019 Jan 14;35(1):125-139.e9. doi: 10.1016/j.ccell.2018.11.018.

2018

Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma.
Sternberg C, Gruber W, Eberl M, Tesanovic S, Stadler M, Elmer DP, Schlederer M, Grund S, Roos S, Wolff F, Kaur S, Mangelberger D, Lehrach H, Hache H, Wierling C, Laimer J, Lackner P, Wiederstein M, Kasper M, Risch A, Petzelbauer P, Moriggl R, Kenner L, Aberger F.
Int J Cancer. 2018 Dec 1;143(11):2943-2954. doi: 10.1002/ijc.31724. Epub 2018 Oct 1.

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.
Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O.
Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018 Aug 3. Review.

The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.
Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R.
Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18.

Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in Mice.
Abu Eid S, Hackl MT, Kaplanian M, Winter MP, Kaltenecker D, Moriggl R, Luger A, Scherer T, Fürnsinn C.
Front Endocrinol (Lausanne). 2018 Aug 28;9:490. doi: 10.3389/fendo.2018.00490. eCollection 2018

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.
Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R.
Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27. Review.

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.
Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.
Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.

NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
Seidi K, Jahanban-Esfahlan R, Monhemi H, Zare P, Minofar B, Daei Farshchi Adli A, Farajzadeh D, Behzadi R, Mesgari Abbasi M, Neubauer HA, Moriggl R, Zarghami N, Javaheri T.
Oncogene. 2018 Jul;37(29):3967-3980. doi: 10.1038/s41388-018-0213-4. Epub 2018 Apr 17.

Afatinib restrains K-RAS-driven lung tumorigenesis.
Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.
Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi:10.1126/scitranslmed.aao2301

Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R.
Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2

Tumor target amplification: Implications for nano drug delivery systems.
Seidi K, Neubauer HA, Moriggl R, Jahanban-Esfahlan R, Javaheri T.
J Control Release. 2018 Apr 10;275:142-161. doi: 10.1016/j.jconrel.2018.02.020. Epub 2018 Feb 16. Review.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.
Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia.
Pham HTT, Hengstschläger M, Moriggl R.
Mol Cell Oncol. 2018 Mar 28;5(3):e1435181. doi: 10.1080/23723556.2018.1435181. eCollection 2018.

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.
Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E.
Vet Comp Oncol. 2018 Mar;16(1):55-68. doi: 10.1111/vco.12311. Epub 2017 Apr 11.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.
Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

AKT3 drives adenoid cystic carcinoma development in salivary glands.
Zboray K, Mohrherr J, Stiedl P, Pranz K, Wandruszka L, Grabner B, Eferl R, Moriggl R, Stoiber D, Sakamoto K, Wagner KU, Popper H, Casanova E, Moll HP.
Cancer Med. 2018 Feb;7(2):445-453. doi: 10.1002/cam4.1293. Epub 2017 Dec 28.

Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. Diabetes 2017;66:272-286.
Mueller KM, Hartmann K, Kaltenecker D, Vettorazzi S, Bauer M, Mauser L, Amann S, Jall S, Fischer K, Esterbauer H, Müller TD, Tschöp MH, Magnes C, Haybaeck J, Scherer T, Bordag N, Tuckermann JP, Moriggl R.
Diabetes. 2018 Feb;67(2):343-344. doi: 10.2337/db18-er02a. Epub 2017 Nov 16.

STAT5BN642H is a driver mutation for T cell neoplasia.
Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R.
J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.
Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R.
Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi:10.1080/14728222.2018.1406924. Epub 2017 Nov 24.

Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.
Kinslechner K, Schörghofer D, Schütz B, Vallianou M, Wingelhofer B, Mikulits W, Röhrl C, Hengstschläger M, Moriggl R, Stangl H, Mikula M.
Mol Cancer Res. 2018 Jan;16(1):135-146. doi: 10.1158/1541-7786.MCR-17-0292. Epub 2017 Oct 3.